[NEWSMP] Among pharmaceutical and biotech companies with a December fiscal year-end included in the Pharmaceuticals Index for the KOSPI and KOSDAQ markets, 46 companies achieved double-digit operating profit margins in the first quarter (based on separate financial statements).
Notably, 14 of these companies posted operating margins exceeding 30%, and 8 companies surpassed 40%, entering the top 100 among the 2,269 December-closing companies with comparable year-over-year data in both markets (excluding financial companies).
According to the Korea Exchange’s recently published first-quarter 2025 earnings report for December-closing companies on the KOSPI and KOSDAQ markets, 550 companies, or a quarter of the total 2,269 companies, recorded double-digit operating margins.
Among the 162 companies in the Pharmaceuticals Index, 46 companies, or about a third, achieved double-digit operating margins.
Leading the pack was Chong Kun Dang Holdings, which achieved an operating margin of 72.9%, ranking 49th among all 2,269 companies across both markets, making it the only company in the Pharmaceuticals Index to place within the top 50.
Next in line were Caregen, Huons Global, Samsung Biologics, PharmaResearch, EuBiologics, T&L, and Bioplus, all of which posted operating margins in the 40% range, securing spots within the top 100.
SunBio, Daewoong, Hugel, BIO-FD&C, Pharmicell, and Sama Pharm followed with operating margins in the 30% range. Meanwhile, Humedix and Boditech Med made it into the top 200 with margins in the 20% range.
Celltrion, Metabiomed, BNC Korea, PanGen, and Wonbiogen also recorded operating margins of over 20%. Korea United Pharm, Bionote, Daihan Pharmaceutical, Choong Ang Vaccine Lab, Hightech Pharm, JW Life Science, and GC Wellbeing posted margins exceeding 16%. All of these companies ranked in the top 300.
Furthermore, Hanmi Pharm, Cell Biotech, Sewoon Medical, HLB Genex, Ildong Holdings, Yuyu Pharma, Seegene, Bukwang Pharm, Daewoong Pharmaceutical, Woogene B&G, Jin Yang Pharm, JW Pharmaceutical, Medytox, Dongkook Pharmaceutical, Theragen Etex, Aminologics, HK inno.N, and Sinil Pharmaceutical all recorded double-digit operating margins.
